Investment Rating - The report maintains a "Buy" rating for Huahong Semiconductor with a target price of HKD 119 [5][11]. Core Insights - The company reported Q3 2025 revenue of USD 635.2 million, a year-on-year increase of 20.7% and a quarter-on-quarter increase of 12.2%, aligning with company guidance [1]. - Gross margin reached 13.5%, exceeding the company's previous guidance of 10%-12%, primarily driven by high capacity utilization and a 5.2% increase in average selling price (ASP) [2][3]. - The company expects Q4 2025 revenue to be between USD 650 million and USD 660 million, with a gross margin guidance of 12%-14% [1]. Summary by Sections Revenue and Profitability - Q3 2025 revenue was USD 635.2 million, with a gross margin of 13.5%, up 1.3 percentage points year-on-year and 2.6 percentage points quarter-on-quarter [1]. - The revenue from analog and power management increased by 32.8% year-on-year to USD 164.8 million, driven by rising demand for power management products [1]. - Standalone non-volatile memory revenue surged by 106.6% year-on-year to USD 60.6 million, attributed to increased demand for flash products [1]. Capacity and Efficiency - The company achieved a capacity utilization rate of 109.5% in Q3, up 1.2 percentage points from the previous quarter, allowing for flexible production prioritizing high-margin products [3]. - Huahong plans to invest approximately USD 2 billion in capital expenditures for Fab 9A in 2025, with expectations to ramp up monthly capacity to 60,000-65,000 wafers by mid-next year [3]. Future Outlook - The report anticipates continued ASP growth and improved overall profitability, supported by strong demand in AI-related power management and storage sectors [1][2]. - The company has raised its net profit forecasts for 2025, 2026, and 2027 by 24%, 15%, and 23% respectively, reflecting the positive impact of ASP and operational efficiency improvements [4].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 35.22 [1][5] Core Views - The company is expected to benefit from the ongoing rise in aluminum prices, which will enhance its performance as the leading player in the global electrolytic aluminum industry [1][3] - The company has implemented a share buyback plan and maintains a high dividend payout ratio, reflecting confidence in future growth and commitment to shareholder returns [4] Financial Performance - The core subsidiary, Shandong Hongqiao New Materials Co., Ltd., reported a revenue of RMB 116.93 billion for the first three quarters, a year-on-year increase of 6.2%, and a net profit of RMB 19.37 billion, up 23.1% year-on-year [2] - In Q3, the company achieved a revenue of RMB 38.72 billion, with a year-on-year and quarter-on-quarter growth of 1.8% [2] - The gross margin for Q3 was 26.6%, an increase of 1.3 percentage points year-on-year and 2.6 percentage points quarter-on-quarter, driven by rising prices of electrolytic aluminum and alumina [2] Market Outlook - The supply of domestic electrolytic aluminum is expected to face constraints, while demand from sectors like automotive and power grids remains strong, indicating a tightening supply-demand balance in 2026 [3] - The alumina market is expected to remain relatively loose, with prices likely to fluctuate downward, but the company’s electrolytic aluminum segment is anticipated to offset the pressure from alumina price declines [3] Shareholder Returns - The company plans to initiate a new share buyback program with a total amount not less than HKD 3 billion, following a previous buyback of HKD 2.6 billion [4] - The dividend payout ratios over the past three years have been 46.8%, 47.0%, and 63.4%, consistently above 45% since 2020, demonstrating a strong commitment to returning value to shareholders [4] Profit Forecast and Valuation - The company’s net profit forecasts for 2025-2027 have been raised to RMB 25.63 billion, RMB 25.43 billion, and RMB 25.76 billion, reflecting increases of 18.31%, 21.72%, and 17.56% respectively [5] - The report assigns a price-to-earnings (P/E) ratio of 12x for 2025, up from a previous estimate of 10x, based on the company's high dividend yield and its unique position in the Hong Kong electrolytic aluminum market [5]

Investment Rating - The report suggests a cautious subscription for Zhongwei Co., Ltd. (2579.HK) [1] Core Insights - The company is a leader in the global market for nickel and cobalt pCAM used in lithium-ion batteries, with market shares of 20.3% and 28.0% respectively in 2024 [2] - The demand for the company's products is driven by applications in electric vehicles, energy storage systems, and consumer electronics, which have significant commercial potential [2] - The global nickel pCAM shipment is expected to grow to 3,103.7 thousand tons by 2030, with a compound annual growth rate (CAGR) of 21.6% from 2024 to 2030 [3] - The company's revenue for 2022, 2023, and 2024 is projected to be RMB 30,343.7 million, RMB 34,273.2 million, and RMB 40,222.9 million respectively, with net profits of RMB 1,539.4 million, RMB 2,100.5 million, and RMB 1,787.8 million [3] Summary by Sections IPO Details - The IPO price range is set at HKD 34 to HKD 37.8, with a total fundraising amount of HKD 3.6279 billion [1] - The total number of shares available for subscription is 10,422.54 million, with 90% allocated for international placement and 10% for public offering [1] Market Position - The company has maintained its position as the top supplier of nickel and cobalt pCAM for five consecutive years since 2020 [2] - The current IPO pricing reflects a significant discount compared to the A-share closing price, providing a safety margin for investors [4] - The estimated PE ratio for 2024 is approximately 23 times, indicating a moderate position within the industry [4] Industry Outlook - The industry for new energy batteries is in a growth phase, with substantial long-term growth potential [4] - The demand for cobalt pCAM is expected to accelerate, with shipments projected to reach 209.8 thousand tons by 2030, reflecting a CAGR of 12.7% from 2024 to 2030 [3]

Investment Rating - The report maintains a "Buy" rating for Kunlun Energy [9] Core Views - The company is expected to achieve dual growth in profitability and dividends, leading to a revaluation of its long-term value [3] - The company has outlined its core business operational trends and significant progress, including retail gas volume growth, LNG industry chain synergy, LPG sales, and crude oil performance [3] Summary by Relevant Sections Business Performance - Retail gas volume growth for the first nine months is expected to return to 5%, driven by high single-digit growth from industrial users [4] - The LNG receiving station is projected to operate at an annual load factor of 85%-90% [4] - LPG sales showed high single-digit growth in the first nine months, with a slight increase expected for the full year [4] - Crude oil production is anticipated to stabilize at 8 million barrels for the year [4] Margin and Cost Trends - The gross margin for the first half was 0.44 RMB per cubic meter, a slight year-on-year decrease of 0.01 RMB, influenced by gas station integration and promotional strategies for industrial users [4] - A stable to slightly increasing gross margin is expected in the second half due to cost optimization in winter [4] - Long-term demand for gas is expected to remain robust, supported by the dual carbon goals and industry pricing mechanisms [4] Long-term Planning and Non-gas Business - The company has clarified its long-term focus on five strategies: innovation, green energy, market, capital, and low cost [5] - The company aims to become a leading comprehensive energy supplier in China, with a natural gas terminal market share expected to match upstream supply [5] - The Shandong 380,000 kW onshore wind power project is planned to be operational by Q3 2026 [5] Dividend Policy - The interim dividend is set at 0.166 RMB per share, reflecting a year-on-year increase of 1.2%, with a payout ratio of 45.5% [4] - The current stock price corresponds to a 2025 estimated dividend yield of 4.8% [4] - The dividend policy for 2023-2025 is expected to be steadily implemented, with a more positive outlook for 2026-2028 [4] Profit Forecast and Valuation - The report maintains the forecast for the company's net profit attributable to the parent company at 6.15 billion, 6.49 billion, and 6.84 billion RMB for 2025-2027, respectively [6] - The target price is set at 8.58 HKD, based on an 11x PE for 2025E and an exchange rate of 0.91 for HKD to RMB [6]

Investment Rating - The report does not explicitly state an investment rating for Zai Lab, but it provides insights into the company's performance and future expectations, which can inform investment decisions. Core Insights - In Q3 2025, Zai Lab reported net product revenue of USD 115 million, representing a year-over-year increase of 13% and a quarter-over-quarter increase of 6% [6] - The company narrowed its net loss to USD 36 million, a 12% improvement from the previous quarter, while adjusted operating loss improved by 18% to USD 28 million [6] - Management has revised the full-year 2025 revenue guidance down to USD 460 million from a previous range of USD 560-590 million [6] Revenue Breakdown - Core product efgartigimod generated sales of USD 27.7 million, up 5% quarter-over-quarter, driven by extended treatment duration and increased market penetration, despite a revenue reduction of approximately USD 2.4 million due to price adjustments [2][8] - Zejula (PARP inhibitor) sales reached USD 42.4 million, a 3% increase quarter-over-quarter [2][8] - Nuzyra (antibiotic) sales were USD 15.4 million, reflecting an 8% quarter-over-quarter increase [2][8] Future Focus - Key milestones anticipated in 2026 include data readouts for Zoci (DLL3 ADC) in the first half of 2026, with registration clinical trials for first-line small cell lung cancer (1L SCLC) and neuroendocrine carcinoma (NEC) expected to start in 2026 [3][8] - Management expects the first overseas approval for an indication in 2027/2028 [3][8] - Other products in the pipeline include ZL-1503 (IL13/IL31) with first-in-human data expected in 2026 and ZL-6201 (LRRC15 ADC) set to initiate global Phase 1 clinical trials in the first half of 2026 [5][8]

Investment Rating - The report maintains a "Buy" rating for the company, expecting a price increase of over 15% in the next 6-12 months [5]. Core Insights - The company reported total revenue of $1.4 billion in Q3 2025, a year-on-year increase of 41%, and achieved a GAAP net profit of $125 million, marking a return to profitability [2]. - The core product, Zebutinib, continues to show rapid growth, with Q3 sales reaching $1.04 billion, up 51% year-on-year and 10% quarter-on-quarter, solidifying its position as a global leader in the BTKi market [3]. - The company has raised its full-year guidance for 2025, projecting total revenue between $5.1 billion and $5.3 billion, with GAAP operating expenses of $4.1 billion to $4.3 billion, and a gross margin in the mid-to-high 80% range [3]. - The research pipeline is advancing efficiently, with several key milestones expected in the near future, including clinical trials for various treatments [4]. - The company has revised its net profit forecasts for 2025-2027 to $312 million, $795 million, and $1.22 billion, respectively, reflecting a positive trend in profitability [5]. Summary by Sections Performance Review - In Q3 2025, the company achieved total revenue of $1.4 billion, a 41% increase year-on-year, and a GAAP net profit of $125 million, indicating a return to profitability [2]. Operational Analysis - Zebutinib sales reached $1.04 billion in Q3 2025, a 51% increase year-on-year, with the U.S. market contributing $739 million (up 47% year-on-year) and Europe showing a 68% increase to $163 million [3]. - The company has updated its full-year guidance for 2025, projecting revenue of $5.1 billion to $5.3 billion and positive GAAP net profit for the year [3]. Research and Development - The company is set to initiate several key clinical trials in 2025 and 2026, including studies for various cancer treatments, indicating a robust R&D pipeline [4]. Profitability Forecast - The company has increased its net profit forecasts for 2025-2027, now expecting $312 million, $795 million, and $1.22 billion, respectively, reflecting a significant improvement in profitability [5].

Investment Rating - The report assigns an "Outperform" rating for BeiGene, indicating an expected total return over the next 12-18 months that exceeds the relevant market benchmark by more than 10% [16]. Core Insights - In Q3 2025, BeiGene achieved revenue of USD 1.4 billion, a year-on-year increase of 41%, and a quarter-on-quarter increase of 7.7% from USD 1.3 billion in Q2 2025. The U.S. market contributed USD 743 million, reflecting an 8.5% increase from the previous quarter. GAAP operating profit was USD 163 million, up 73.4% quarter-on-quarter [5][6]. - Management has updated its full-year guidance for 2025, projecting total revenue between USD 5.1 billion and USD 5.3 billion, with GAAP operating expenses expected to be between USD 4.1 billion and USD 4.3 billion [5][6]. Revenue Breakdown - Global revenue for Zanubrutinib reached USD 1.0 billion, representing a 51% year-on-year increase and a 5.3% quarter-on-quarter increase. In the U.S., revenue was USD 740 million, up 47% year-on-year and 8% quarter-on-quarter. European revenue was USD 160 million, a 68% year-on-year increase and an 8.7% quarter-on-quarter increase [2][6]. - Tislelizumab revenue in Q3 2025 was USD 190 million, reflecting a 17% year-on-year increase but a slight decline of 1.5% quarter-on-quarter [6]. Clinical Development Progress - Sonrotoclax (BCL2 inhibitor) received Breakthrough Therapy Designation for RR MCL, and patient enrollment for a potential registrational Phase 2 study in RR WM has been completed [7]. - BGB-16673 (BTK CDAC) has initiated a global Phase 3 trial against pirtobrutinib in R/R CLL, with patient enrollment currently underway [7]. - BGB-45035 (IRAK4 CDAC) has started a Phase 2 trial for moderate-to-severe rheumatoid arthritis, with patient enrollment initiated [7]. Expected R&D Milestones - BGB-43395 (CDK4 inhibitor) plans to initiate a Phase 3 trial in 1L HR+/HER2- breast cancer in H1 2026 [8]. - BGB-16673 (BTK CDAC) expects data readout in R/R CLL in H1 2026 to support an accelerated approval application [8]. - Sonrotoclax plans to initiate patient enrollment for a Phase 3 trial combining with BTK inhibitor versus acalabrutinib + venetoclax in H1 2026, and a Phase 3 trial in multiple myeloma in H2 2026 [8].

[Table_Title] 研究报告 Research Report 6 Nov 2025 银河娱乐 Galaxy Entertainment (27 HK) 25Q3 EBITDA 利润率略有下滑，市场份额维稳 Adjusted EBITDA Margin Slightly Declined in 25Q3, while Market Share Remained Stable27 寇媛媛 Yuanyuan Kou 骆雅丽 Yali Luo yy.kou@htisec.com yl.luo@htisec.com [Table_yemei1] 热点速评 Flash Analysis [(PTable_summary] lease see APPENDIX 1 for English summary) 事件: 银河娱乐发布 25Q3 业绩，公司实现净收益 121.6 港元，同比提升 14.0%；经调整 EBITDA 达 33.4 亿港元，同 比提升 13.6%，对应经调整 EBITDA 利润率为 27.5%，同比下滑 0.1 个百分点。截至 25Q3，公司总收益达 354.1 亿港 元，同比提升 10.2%；经 ...

证券研究报告 商贸零售 | 互联网电商 港股|公司点评报告 hyzqdatemark 2025 年 11 月 06 日 证券分析师 陈良栋 SAC：S1350524100003 chenliangdong@huayuanstock.com 陈逸凡 SAC：S1350525040003 chenyifan@huayuanstock.com 市场表现： | 基本数据 | 2025 年 | | 11 月 | 05 | 日 | | --- | --- | --- | --- | --- | --- | | 收盘价（港元） | | | | 158.50 | | | 一年内最高/最低（港 | | 186.20/77.35 | | | | | 元） | | | | | | | 总市值（百万港元） | | 3,025,549.02 | | | | | 流通市值（百万港元） | | 3,025,549.02 | | | | | 资产负债率（%） | | | | 40.81 | | | 资料来源：聚源数据 | | | | | | 阿里巴巴-W(09988.HK) 投资评级： 买入（维持） ——FY26Q2 预计阿里云营收增长提速 ...

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [1]. Core Insights - The company is a global leader in automotive micro-motors and systems, with a complete global manufacturing system and stable Tier 1 customer resources. Revenue projections for 2026E-2028E are $3.816 billion, $4.100 billion, and $4.634 billion, respectively, with corresponding net profits of $271 million, $297 million, and $339 million. The company’s valuation shows significant attractiveness compared to A-share and global peers [7]. Summary by Sections 1. Global Leading Micro-Motor Manufacturer - The company has evolved through three stages since its establishment in 1959, transitioning from toy micro-motors to automotive electric motors and expanding into various fields through acquisitions [18]. 2. Main Business: APG Growth Amid Electrification - The company’s automotive product group (APG) is expected to see volume and price increases due to the transition from fuel vehicles to electric vehicles. The average number of motors in electric vehicles is approximately 17 times that of fuel vehicles, leading to a significant increase in single-vehicle value [8][51]. 3. Key Assumptions - The company’s APG business is projected to benefit from the growth in electric vehicle production, with global electric vehicle output expected to rise from 24.9 million units in 2024 to 40.2 million units in 2028, reflecting a CAGR of 12.7% [8]. - The humanoid robot business is anticipated to become a core supplier for domestic and international manufacturers, leveraging its global manufacturing layout and system-level motor technology [8]. - The AI data center liquid cooling pump business is expected to benefit from the growing demand for cooling efficiency, with the market projected to grow from $2 billion in 2024 to $72.89 billion by 2030 [8]. 4. Financial Forecast and Valuation - The company’s projected revenues and net profits for 2026E-2028E are $3.816 billion, $4.100 billion, and $4.634 billion, and $271 million, $297 million, and $339 million, respectively. The corresponding P/E ratios are 15.2, 13.9, and 12.2 [10][12]. 5. Market Perception - Contrary to common perceptions that the company’s growth is constrained by the automotive cycle, the report highlights the company’s capabilities in high-precision motors and fluid control systems, which provide a strong foundation for growth in emerging sectors [11]. 6. Revenue Structure and Growth - The company’s revenue structure is increasingly concentrated in the automotive sector, with APG expected to account for 84% of total revenue by 2025. The company’s global customer base includes major automotive manufacturers and high-end brands across various industries [20][33]. 7. Electric Vehicle Market Dynamics - The report indicates that the global automotive industry is transitioning from quantity growth to structural optimization, with electric vehicles becoming the primary source of growth. The penetration rate of electric vehicles is expected to rise significantly, driving revenue growth for the company [55][56]. 8. Single Vehicle Value Enhancement - The average single vehicle value for electric vehicles is projected to be significantly higher than that of fuel vehicles, with estimates of $326.5 for electric vehicles compared to $217.6 for fuel vehicles [56].